Evidence map›Paper›PMID 34409210›Full record

ArticleAdvances in radiation oncology

Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue.

Omran Saifi, Scott C Lester, William Rule, Bradley J Stish, Scott Stafford, Deanna H Pafundi, Liuyan Jiang, David Menke, Muhamad Alhaj Moustafa, Allison Rosenthal and 5 more

Abstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Definitive 24 Gy radiotherapy for stage IE gastric MALT lymphoma: large-scale validation of an optimal dose with reduced acute toxicity.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Omran SaifiDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida.
Scott C LesterDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
William RuleDepartment of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
Bradley J StishDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Scott StaffordDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Deanna H PafundiDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida.
Liuyan JiangDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Florida.
David MenkeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Florida.
Muhamad Alhaj MoustafaDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.
Allison RosenthalDivision of Hematology-Oncology, Mayo Clinic, Phoenix, Arizona.
Taimur SherDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.
Ayala ErnestoDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.
Han W TunDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, Florida.
Bradford S HoppeDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida.
Jennifer L PetersonDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study compares reduced (<27 Gy) to standard dose (≥30 Gy) radiation therapy (RT) in the treatment of gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (gMALT lymphoma). METHODS AND MATERIALS: Forty-two patients with stage I or II disease were retrospectively reviewed. Response to RT was assessed with endoscopy after RT. Complete response rate (CR), freedom from treatment failure, and overall survival (OS) were calculated.

resultsAll patients were stage I (n = 40) or II (n = 2). All patients had residual biopsy proven gMALT lymphoma before RT. Twenty-six patients (61.9%) were treated with standard dose RT, 30 to 36 Gy, and 16 (38.1%) with the reduced dose RT, 23.5 to 27 Gy. The median follow-up was 29.5 months (range, 6-85). Thirty-six patients (86%) achieved complete response (CR), and 6 patients (14%) achieved partial response (PR). The complete response rate (CR) at the first endoscopic assessment, median time of 3 months, was 81% (95% confidence interval, 0.61%-0.93%) for standard RT, and 94% (confidence interval, 0.69%-0.99%) for reduced RT. Among CR patients, one patient had locally relapsed disease at 50 months. The 1-year overall survival (OS) was 100% in both groups. The 1-year freedom from treatment failure (FFTF) was 100% in the reduced RT group and 92% in the standard RT group. The 2-year FFTF and OS of the whole cohort were 92% and 96%, respectively. There was no significant difference in the OS, FFTF, and CR between the 2 treatment groups (

conclusionsReduced dose RT (23.5-27 Gy) achieved excellent complete response rates with minimal toxicity, comparable with standard dose RT (30-36 Gy), for gMALT.

Identifiers

PMID34409210
PMCPMC8361052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.